Targeting DCAF5 to stabilize the SWI/SNF complex thus emerges as a potential strategy to inhibit SMARCB1-mutant cancers<sup>70.</sup>Recent studies have explored the therapeutic potential of nanoparticle-based drug delivery systems to expand treatment options for SMARCB1-deficient tumors. Here, SMARCA1 is linked to cancer.